> Antigen, Antibodies, ELISA, Western Blot > Primary Antibody > Polyclonal Antibodies > BRCC36 AntibodyBrand |
Leading Biology | Catalog Number |
APR06461G |
Product Type |
Polyclonal Antibodies | Field of Research |
|
Product Overview |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality BRCC36 Antibody.
|
||
Molecular Weight |
36072 Da
|
||
Cellular Localization |
Antigen Cellular Localization:
Nucleus. Note=Localizes at sites of DNA damage at double-strand breaks (DSBs)
|
||
Host |
Rabbit
|
||
Species Reactivity |
Human, Mouse, Rat
|
||
Target |
BRCC3;
|
||
Isotype |
IgG
|
||
Symbol |
BRCC36, C6.1A, CXorf53
|
||
GeneID |
|||
UniProt ID |
|||
Function |
Metalloprotease that specifically cleaves 'Lys-63'- linked polyubiquitin chains. Does not have activity toward 'Lys- 48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double- strand breaks (DSBs). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates. Mediates the specific 'Lys-63'- specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex.
|
||
Summary |
BRCC36 Antibody: Together with the breast and ovarian predisposition proteins BRCA1 and BRCA2 and RAD51 and BRCC45, BRCC36 forms a holoenzyme complex that possesses a ubiquitin E3 ligase activity. Aberrant levels of BRCC36 were detected in sporadic breast tumors and depletion of either BRCC36 or BRCC45 by siRNA resulted in increased sensitivity to ionizing radiation and defects in the G2/M checkpoint, indicating that BRCC36 acts to enhance cellular survival following DNA damage. Recent experiments have shown that BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation, suggesting that BRCC36 may be an important target in the treatment of radiation-resistant breast tumors. At least two isoforms of BRCC36 are known to exist.
|
||
Storage & Stability |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
Applications |
WB, IHC-P, IF, E
|
||
Images |
|
||
Specification |
|||
Quantity |
|
||
| Select | Brand | Catalog No. | Product Name | Pack Size | Type | Field of Research | Specification | Quantity | Price(USD) | |
| 1 | Leading Biology | APR03440G | ITGA11 Antibody (N-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 2 | Leading Biology | APR04537G | CMIP Antibody (C-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 3 | Leading Biology | APR12422G | Human H4 Histamine Receptor (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
$695.00 | Add Ask | ||
| 4 | Leading Biology | APR03844G | UBE2W Antibody (C-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 5 | Leading Biology | APR04349G | HECTD2 Antibody (N-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 6 | Leading Biology | APR03502G | IGHG1 Antibody (Center) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask |
Leading Biology Inc.
2600 Hilltop DR, Building G, B Suite C138
Richmond, CA, 94806
Tel: 1-661-524(LBI)-0262
Email: info@leadingbiology.com
You have 0 item in your cart
You have 0 item in your inquiry list
